Cord blood clinical trials
Excitingly, 30 of these are looking at autologous cord blood use to treat conditions including diabetes, cerebral palsy, hearing loss, brain injury and more.
- Monash University (VIC) has just approved an ethics application to establish a clinical trial for the use of autologous cord blood to treat cerebral palsy and brain injury. This trial will be supported by Cell Care Australia.
- Cell Care Australia is also working with researchers in NSW to develop a protocol for a trial of autologous cord blood use in Type 1 Diabetes.
- Duke University USA. A two-year study looking at the effect of infusing autologous cord blood in 120 children with spastic cerebral palsy.
- Medical College of Georgia, USA. A study looking at the safety and effectiveness of a cord blood infusion in 40 children who have motor disability due to cerebral palsy.
- Technische Universität München, Germany. A pilot study looking at the effect of transfusion of autologous umbilical cord blood in 23 children to reverse hyperglycemia in children with Type 1 Diabetes.
- University of Florida, USA. A study looking at the effect of transfusion of autologous umbilical cord blood in 23 children to reverse hyperglycemia in children with Type 1 Diabetes.
- University of Florida, USA. A study looking at whether a combination of vitamin D and Omega 3 can augment the autoimmune response in Type 1 Diabetes in children infused with autologous umbilical cord blood.
- TCA Cellular Therapy, USA. This study seeks to assess the safety and tolerance of an intrathecal infusion (lumbar puncture) of autologous, ex-vivo expanded bone marrow-derived mesenchymal stem cells in a well-defined population of spinal cord injury patients.
- Gamida Cell-Teva Joint Venture Ltd, USA, Israel. This study is looking
at assessing the safety and effectiveness of transplanting StemEx in patients with blood disorders. The StemEx technology is based on reducing the amount of copper present in cells as this has been shown to delay cell differentiation and prolong proliferation. Early pre-clinical data shows that the resulting population of cells contains increased numbers of blood stem cells with increased ability to self-renew. Their phase 3 trial is looking using a mixture of stem cells isolated and expanded from a portion of a single unit of cord blood and then transplanted together with non-expanded cells from the same unit to treat adults with leukemia, lymphoma and other blood related malignancies.
want to know more?
For more articles, local directories of shops and services, checklists, calculators and more visit our...:: pregnancy & birth info hub